Lupin Limited announced that it will pay Sunovion $75 million for the rights to Brovana arformoterol inhalation solution and Xopenex HFA levalbuterol MDI. Brovana has been approved in the US for the treatment of COPD since 2006, and Lupin launched an authorized generic of the inhalation solution in June 2021. Xopenex was initially approved for the treatment of asthma … [Read more...] about Lupin acquires US rights to Brovana inhalation solution and Xopenex HFA MDI
Business
Hibiocy enters contract with Genscript for manufacturing of Covitrap nasal spray for the prevention of COVID-19
According to CDMO GenScript ProBio, the company has signed an agreement with Thai company Hibiocy for manufacturing of Covitrap, an intranasal antibody cocktail for the prevention of COVID-19. GenScript said that the deal includes both clinical trial and commercial manufacturing of Covitrap, as well as work on development of new products. The company said that … [Read more...] about Hibiocy enters contract with Genscript for manufacturing of Covitrap nasal spray for the prevention of COVID-19
Transpire Bio announces development deal with INTO and names new Chief Scientific Officer
Transpire Bio, which previously announced deals with Recipharm for development of four inhaled products, announced a new deal with INTO (Inhalation Together) for development of three additional inhaled products: TRB-5, TRB-6 and TRB-7. INTO is a partnership between DFE Pharma, Sterling, and Harro Höfliger that was formed earlier this year to provide early development … [Read more...] about Transpire Bio announces development deal with INTO and names new Chief Scientific Officer
Odyssey Health creates subsidiary for development of intranasal drugs
Odyssey Health has announced the creation of a subsidiary called Odyssey Neuropharma that will develop intranasal drugs for the treatment of neurological disorders, including PRV-002 intranasal synthetic neurosteroid for the treatment of concussion. In addition to PRV-002, the company says that it intends to develop spray-dried dry powder nasal formulations for the … [Read more...] about Odyssey Health creates subsidiary for development of intranasal drugs
Blue Water to develop its intranasal S. pneumoniae vaccine for the prevention of pneumococcal pneumonia
Blue Water Vaccines said that it intends to develop its BWV-201 intranasal Streptococcus pneumoniae vaccine candidate for the prevention of non-invasive pneumococcal pneumonia. The company is already developing the live attenuated intranasal vaccine, which it licensed from St. Jude Children’s Research Hospital, for the prevention of acute otitis media in children. … [Read more...] about Blue Water to develop its intranasal S. pneumoniae vaccine for the prevention of pneumococcal pneumonia
Intravacc gets funding for intranasal gonorrhea and betacoronavirus vaccines
Dutch intranasal vaccine developer and CDMO Intravacc said that it has received an award of up to $14.6 million from the US National Institute of Allergy and Infectious Diseases (NIAID) to support development of an intranasal vaccine against gonorrhea and another award of up to $4.8 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support … [Read more...] about Intravacc gets funding for intranasal gonorrhea and betacoronavirus vaccines
Pfizer completes acquisition of Biohaven and its zagevepant nasal spray
Pfizer has completed its acquisition of Biohaven Pharmaceutical, including Biohaven's intranasal zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist, the company said. Pfizer announced that it had acquired the ex-US rights to zavegepant and Nurtec ODT rimegepant from Biohaven January 2022. By the time that the FDA accepted Biohaven's NDA … [Read more...] about Pfizer completes acquisition of Biohaven and its zagevepant nasal spray
HCmed Innovations and AeroRx Therapeutics partner on nebulized LABA/LAMA for COPD
Startup inhaled drug developer AeroRx Therapeutics and nebulizer maker HCmed Innovations have announced that they will partner on development of a nebulized LABA/LAMA inhalation solution for the treatment of COPD. AeroRx is a spinoff of iPharma Labs, which was acquired by Kindeva Drug Delivery earlier this year. In March 2022, HCmed announced that it was partnering … [Read more...] about HCmed Innovations and AeroRx Therapeutics partner on nebulized LABA/LAMA for COPD
Transpire Bio contracts with Recipharm for development of two more inhaled drugs
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional two inhaled products. Under the new agreement, Recipharm will provide development services for Transpire's TRB-3 and TRB-4 inhaled therapeutics for the … [Read more...] about Transpire Bio contracts with Recipharm for development of two more inhaled drugs
Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis
Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to rights to the Washington University intranasal COVID-19 vaccine outside of the United States, Europe, and Japan, and Bharat recently … [Read more...] about Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis